Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
Total Valuation
Allogene Therapeutics has a market cap or net worth of $587.50M. The enterprise value is $619.07M.
Market Cap$587.50M
Enterprise Value$619.07M
Share Statistics
Allogene Therapeutics has 243,777,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding243,777,920
Owned by Insiders9.47%
Owned by Institutions30.29%
Financial Efficiency
Allogene Therapeutics’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -53.97%.
Return on Equity (ROE)-0.65
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-53.97%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee0.00
Profits Per Employee-844.63K
Employee Count226
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Allogene Therapeutics is ―. Allogene Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio0.00
PB Ratio1.03
Price to Fair Value1.03
Price to FCF-2.02
Price to Operating Cash Flow-3.56
PEG Ratio0.05
Income Statement
In the last 12 months, Allogene Therapeutics had revenue of 0.00 and earned -190.89M in profits. Earnings per share was -0.87.
Revenue0.00
Gross Profit-12.36M
Operating Income-206.93M
Pretax Income-190.89M
Net Income-190.89M
EBITDA-194.57M
Earnings Per Share (EPS)-0.87
Cash Flow
In the last 12 months, operating cash flow was -149.25M and capital expenditures -386.00K, giving a free cash flow of -149.63M billion.
Operating Cash Flow-149.25M
Free Cash Flow-149.63M
Free Cash Flow per Share-0.61
Dividends & Yields
Allogene Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.72
52-Week Price Change55.48%
50-Day Moving Average2.06
200-Day Moving Average1.47
Relative Strength Index (RSI)53.90
Average Volume (3m)5.56M
Important Dates
Allogene Therapeutics upcoming earnings date is May 6, 2026, Before Open (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 6, 2026
Ex-Dividend Date―
Financial Position
Allogene Therapeutics as a current ratio of 7.93, with Debt / Equity ratio of 28.46%
Current Ratio7.93
Quick Ratio7.93
Debt to Market Cap0.00
Net Debt to EBITDA-0.12
Interest Coverage Ratio-192.50
Taxes
In the past 12 months, Allogene Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Allogene Therapeutics EV to EBITDA ratio is -1.67, with an EV/FCF ratio of -2.18.
EV to Sales0.00
EV to EBITDA-1.67
EV to Free Cash Flow-2.18
EV to Operating Cash Flow-2.18
Balance Sheet
Allogene Therapeutics has $250.21M in cash and marketable securities with $83.25M in debt, giving a net cash position of $166.96M billion.
Cash & Marketable Securities$250.21M
Total Debt$83.25M
Net Cash$166.96M
Net Cash Per Share$0.68
Tangible Book Value Per Share$1.33
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Allogene Therapeutics is $8.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.71
Price Target Upside261.41% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast-100.00%
EPS Growth Forecast37.10%